HOTH

Expansion of Clinical Trials: Hoth Therapeutics, Inc. is extending its Phase II trial for HT-001 in cancer patients experiencing skin toxicities from EGFR inhibitors, with plans to include multiple sites in the EU pending regulatory approval.

Strategic Partnership: The company has partnered with ICON Clinical Research to enhance its clinical trial management and aims to establish a foundation for a future global Phase III trial while currently enrolling patients in the U.S.

Collaboration Announcement: Hoth Therapeutics has entered a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs and FAVER to study GDNF as a treatment for obesity and fatty liver disease, comparing its effects against semaglutide in animal models.

Study Details and Significance: The research will involve daily GDNF injections in mice and human liver chimeric models, aiming to assess weight loss and metabolic improvements, marking a significant step in exploring GDNF's potential beyond central nervous system applications.

Joint Venture Announcement: Silo Pharma has entered a non-binding letter of intent to form a 50:50 joint venture with Hoth Therapeutics to develop a treatment for obesity and metabolic diseases, utilizing technology licensed from the U.S. Department of Veterans Affairs and co-developed with Emory University.

Potential Impact: The collaboration aims to address the significant health issue of obesity, which affects over 40% of U.S. adults, particularly veterans, by leveraging a biologic called GDNF that has shown anti-obesity effects in preclinical models.